IGFBP3 is a specific biomarker associated with drug resistance of neuroblastoma cells to doxorubicin [76], gastric cancer cells to cisplatin [77], human epidermal growth factor receptor 2 (HER2) positive breast cancer to trastuzumab [78], lung adenocarcinoma harboring an EGFR mutation to afatinib [79], ovarian cancer to cisplatin [80], and non-small cell lung cancer (NSCLC) cells to docetaxel or gemcitabine [81]. This evidence concerns the gene IGFBP3 and non-small cell lung carcinoma.